Accordingly, mutant cyclic peptides of MBP87-99 (e.g., cyclo(91-99)[Ala96]MBP87-99 and cyclo(87-99)[Arg91Ala96]MBP87-99) were shown to suppress the proliferation of a CD4 T-cell line from a MS patient, bind to HLA-DR4 and exhibit an increased Th2/Th1 cytokine ratio in peripheral BMCs derived from MS patients [83]. The gene discussed is NELFCD; the disease is myeloid sarcoma.